MX2015010407A - Heterociclos triciclicos como agentes anticancer. - Google Patents
Heterociclos triciclicos como agentes anticancer.Info
- Publication number
- MX2015010407A MX2015010407A MX2015010407A MX2015010407A MX2015010407A MX 2015010407 A MX2015010407 A MX 2015010407A MX 2015010407 A MX2015010407 A MX 2015010407A MX 2015010407 A MX2015010407 A MX 2015010407A MX 2015010407 A MX2015010407 A MX 2015010407A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- anticancer agents
- tricyclic heterocycles
- tricyclic
- benzenesulfonamide
- Prior art date
Links
- 239000002246 antineoplastic agent Substances 0.000 title 1
- 125000000169 tricyclic heterocycle group Chemical group 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- GYVFCZBDFRLTIS-UHFFFAOYSA-N 4-chloro-n-[3-(5,6-dihydropyrido[3,2-b][1]benzazepin-11-yl)propyl]benzenesulfonamide Chemical compound C1=CC(Cl)=CC=C1S(=O)(=O)NCCCN1C2=CC=CN=C2CCC2=CC=CC=C21 GYVFCZBDFRLTIS-UHFFFAOYSA-N 0.000 abstract 1
- 208000002874 Acne Vulgaris Diseases 0.000 abstract 1
- 101001059929 Caenorhabditis elegans Forkhead box protein O Proteins 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 206010000496 acne Diseases 0.000 abstract 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/78—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
- C07D333/80—Seven-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Psychology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361766387P | 2013-02-19 | 2013-02-19 | |
| PCT/US2014/017127 WO2014130534A1 (en) | 2013-02-19 | 2014-02-19 | Tricyclic heterocycles as anticancer agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2015010407A true MX2015010407A (es) | 2015-10-26 |
Family
ID=51391756
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015010407A MX2015010407A (es) | 2013-02-19 | 2014-02-19 | Heterociclos triciclicos como agentes anticancer. |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US9796717B2 (https=) |
| EP (1) | EP2958565A4 (https=) |
| JP (1) | JP2016508521A (https=) |
| KR (1) | KR20150119390A (https=) |
| CN (1) | CN105073117A (https=) |
| AU (1) | AU2014219042A1 (https=) |
| BR (1) | BR112015019818A2 (https=) |
| CA (1) | CA2901493A1 (https=) |
| IL (1) | IL240612A0 (https=) |
| MX (1) | MX2015010407A (https=) |
| RU (1) | RU2015139700A (https=) |
| SG (1) | SG11201506450RA (https=) |
| WO (1) | WO2014130534A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015138500A1 (en) | 2014-03-11 | 2015-09-17 | Icahn School Of Medicine At Mount Sinai | Sulfonamides derived from tricyclyl-2-aminocycloalkanols as anticancer agents |
| WO2015138496A1 (en) | 2014-03-11 | 2015-09-17 | Icahn School Of Medicine At Mount Sinai | Constrained tricyclic sulfonamides |
| WO2017044575A1 (en) * | 2015-09-09 | 2017-03-16 | Icahn School Of Medicine At Mount Sinai | Constrained benzhydryl sulfonamides as anticancer and neuroprotective agents |
| CA2997784A1 (en) * | 2015-09-09 | 2017-03-16 | Icahn School Of Medicine At Mount Sinai | Heterocyclic constrained tricyclic sulfonamides as anti-cancer agents |
| CA2997769A1 (en) | 2015-09-09 | 2017-03-16 | Icahn School Of Medicine At Mount Sinai | Heterocyclic constrained tricyclic sulfonamides as anti-cancer agents |
| WO2023164940A1 (zh) * | 2022-03-04 | 2023-09-07 | 中国福利会国际和平妇幼保健院 | 氮杂吩噻嗪类化合物及其在制备治疗子宫内膜癌的药物中的应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4634766A (en) | 1983-10-31 | 1987-01-06 | Merck Frosst Canada, Inc. | 1,4-diaza-phenothiazines |
| GB8510680D0 (en) | 1985-04-26 | 1985-06-05 | Smith Kline French Lab | Pyridine derivatives |
| US4882351A (en) | 1987-10-14 | 1989-11-21 | Roussel Uclaf | Tricyclic compounds |
| US5834462A (en) | 1993-07-26 | 1998-11-10 | Eisai Co., Ltd. | Tricyclic heterocyclic sulfonamide and sulfonic ester derivatives |
| WO1997030038A1 (en) | 1996-02-15 | 1997-08-21 | Mitsubishi Chemical Corporation | Diarylsultam derivatives |
| US6333322B1 (en) | 1996-03-13 | 2001-12-25 | Eisai Co., Ltd. | Nitrogen-containing tricyclic compounds and drugs containing the same |
| PE86199A1 (es) * | 1997-06-17 | 1999-09-24 | Schering Corp | Sulfonamida inhibidor de la enzima farnesilo transferasa |
| AU2641899A (en) | 1998-02-27 | 1999-09-15 | Eisai Co. Ltd. | Heterocycle-fused benzothiazine derivatives |
| WO2002024657A2 (en) * | 2000-09-20 | 2002-03-28 | Schering Corporation | Substituted imidazoles as dual histamine h1 and h3 agonists or antagonists |
| TW200400816A (en) | 2002-06-26 | 2004-01-16 | Lilly Co Eli | Tricyclic steroid hormone nuclear receptor modulators |
| IT1362675B (it) | 2005-03-15 | 2009-06-25 | Menarini Internat Operations Luxembourg Sa | N-idrossiammidi -sostituiti con gruppi triciclici come inibitori dell'istone deacelitasi,loro preparazione ed impiego in formulazioni farmaceutiche |
| AU2006239929B2 (en) | 2005-04-22 | 2011-11-03 | Alantos Pharmaceuticals Holding, Inc. | Dipeptidyl peptidase-IV inhibitors |
| GB0508992D0 (en) | 2005-05-03 | 2005-06-08 | Novartis Ag | Organic compounds |
| HK1198384A1 (en) | 2011-08-16 | 2015-04-17 | Mt. Sinai School Of Medicine | Tricyclic compounds as anticancer agents |
| AU2013305591B2 (en) | 2012-08-24 | 2017-04-13 | Board Of Regents Of The University Of Texas System | Pro-neurogenic compounds |
| CN102942562B (zh) | 2012-12-05 | 2014-10-01 | 天津市斯芬克司药物研发有限公司 | 一种苯并咪唑衍生物及其制备方法和应用 |
| WO2015138500A1 (en) | 2014-03-11 | 2015-09-17 | Icahn School Of Medicine At Mount Sinai | Sulfonamides derived from tricyclyl-2-aminocycloalkanols as anticancer agents |
| WO2015138496A1 (en) | 2014-03-11 | 2015-09-17 | Icahn School Of Medicine At Mount Sinai | Constrained tricyclic sulfonamides |
-
2014
- 2014-02-19 BR BR112015019818A patent/BR112015019818A2/pt not_active IP Right Cessation
- 2014-02-19 KR KR1020157025564A patent/KR20150119390A/ko not_active Withdrawn
- 2014-02-19 CN CN201480009539.1A patent/CN105073117A/zh active Pending
- 2014-02-19 RU RU2015139700A patent/RU2015139700A/ru not_active Application Discontinuation
- 2014-02-19 JP JP2015558219A patent/JP2016508521A/ja active Pending
- 2014-02-19 WO PCT/US2014/017127 patent/WO2014130534A1/en not_active Ceased
- 2014-02-19 AU AU2014219042A patent/AU2014219042A1/en not_active Abandoned
- 2014-02-19 SG SG11201506450RA patent/SG11201506450RA/en unknown
- 2014-02-19 EP EP14754200.5A patent/EP2958565A4/en not_active Withdrawn
- 2014-02-19 US US14/768,632 patent/US9796717B2/en active Active
- 2014-02-19 CA CA2901493A patent/CA2901493A1/en not_active Abandoned
- 2014-02-19 MX MX2015010407A patent/MX2015010407A/es unknown
-
2015
- 2015-08-17 IL IL240612A patent/IL240612A0/en unknown
-
2017
- 2017-09-19 US US15/708,916 patent/US20180002339A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US9796717B2 (en) | 2017-10-24 |
| JP2016508521A (ja) | 2016-03-22 |
| EP2958565A4 (en) | 2016-07-27 |
| KR20150119390A (ko) | 2015-10-23 |
| RU2015139700A (ru) | 2017-03-27 |
| US20150376191A1 (en) | 2015-12-31 |
| EP2958565A1 (en) | 2015-12-30 |
| BR112015019818A2 (pt) | 2017-07-18 |
| IL240612A0 (en) | 2015-10-29 |
| US20180002339A1 (en) | 2018-01-04 |
| WO2014130534A1 (en) | 2014-08-28 |
| CN105073117A (zh) | 2015-11-18 |
| AU2014219042A1 (en) | 2015-09-17 |
| SG11201506450RA (en) | 2015-09-29 |
| CA2901493A1 (en) | 2014-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2015010407A (es) | Heterociclos triciclicos como agentes anticancer. | |
| PH12019502318A1 (en) | Trycyclic heterocycles as bet protein inhibitors | |
| CL2016002735A1 (es) | Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer | |
| PH12015501720A1 (en) | Modulators of methyl modifying enzymes, compositions and uses thereof | |
| MX2016001037A (es) | Inhibidores de factores de transcripción y usos. | |
| MY203474A (en) | Substituted tricyclic compounds as fgfr inhibitors | |
| MX2016008131A (es) | Compuestos heterociclos biciclicos y sus usos en terapia. | |
| MX386480B (es) | Inhibidores de hpk1 y métodos de uso de los mismos. | |
| BR112017020952A2 (pt) | método de tratamento de câncer, composição e uso da composição | |
| WO2013025882A3 (en) | Tricyclic compounds as anticancer agents | |
| MX2016007928A (es) | Compuestos triciclicos como agentes anticancerigenos. | |
| PH12016500055B1 (en) | N,6-bis(aryl or heteroaryl)-1,3,5-triazine-2,4-diamine compounds as idh2 mutants inhibitors for the treatment of cancer | |
| EA201591340A1 (ru) | Модулятор андрогенного рецептора и его применения | |
| NZ612788A (en) | Pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators | |
| PE20140864A1 (es) | COMPUESTO DE IMIDAZO[4,5-C]QUINOLIN-2-ONA COMO INHIBIDOR DE PI3K/mTOR | |
| CL2013000016A1 (es) | Compuestos derivados de imidazopiridina; procedimiento de preparacion; composicion farmaceutica y su uso en el tratamiento del cancer. | |
| MY172156A (en) | Modulators of methyl modifying enzymes, compositions and uses thereof | |
| BR112015011760A2 (pt) | composto, uso do composto, e uso de uma composição farmacêutica | |
| HK1218506A1 (zh) | 治療黑素瘤的方法 | |
| AU2011360938A8 (en) | Novel modulators and methods of use | |
| MX2013005994A (es) | Monobactamas. | |
| HK1245632A1 (zh) | 包含癌症干性抑制剂的组合物和用於治疗癌症的免疫治疗剂 | |
| UA114656C2 (uk) | Похідні піридину | |
| AU2019257509A1 (en) | Androgen receptor modulators and methods for their use | |
| TW201613935A (en) | Tricyclic heterocycles as BET protein inhibitors |